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Abstract
Overdose deaths have reached unprecedented levels in the U.S., despite effective medications to treat
opioid use disorders (OUDs). Because the regulatory and administrative barriers to treatment are high,
only about 11% of people with OUD receive effective medications, which include buprenorphine,
methadone, and naltrexone. In response, clinicians and advocates have looked to a “low-threshold”
approach that reduces the stigma surrounding effective medications and facilitates their use. This brief
summarizes the barriers to treatment, the evidence on the low-threshold approach, and areas for future
research. The evidence suggests that low-threshold approaches can increase access to treatment, with
outcomes comparable to high-barrier, standard care. Policymakers, providers, and payers should lower
the barriers to medication treatment through regulatory flexibility (including telehealth prescribing), and
harm reduction strategies that de-emphasize abstinence and place a priority on initiating or re-initiating
treatment whenever and wherever individuals are ready to do so.
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Lowering the Barriers to Medication Treatment
for People with Opioid Use Disorder
Evidence for a Low-Threshold Approach
Shoshana V. Aronowitz, PhD, MSHP, FNP-BC, Czarina Navos Behrends, PhD, MPH, Margaret Lowenstein, MD,
MPhil, MSHP, Bruce R. Schackman, PhD, MBA, and Janet Weiner, PhD, MPH

Overdose deaths have reached unprecedented levels in the U.S., despite effective medications to treat opioid use
disorders (OUDs). Because the regulatory and administrative barriers to treatment are high, only about 11%
of people with OUD receive effective medications, which include buprenorphine, methadone, and naltrexone.
In response, clinicians and advocates have looked to a “low-threshold” approach that reduces the stigma
surrounding effective medications and facilitates their use. This brief summarizes the barriers to treatment,
the evidence on the low-threshold approach, and areas for future research. The evidence suggests that lowthreshold approaches can increase access to treatment, with outcomes comparable to high-barrier, standard
care. Policymakers, providers, and payers should lower the barriers to medication treatment through regulatory
flexibility (including telehealth prescribing), and harm reduction strategies that de-emphasize abstinence and
place a priority on initiating or re-initiating treatment whenever and wherever individuals are ready to do so.
INTRODUCTION
With overdose deaths in the U.S. reaching unprecedented
levels in 2021, it becomes increasingly urgent to find new
ways to deliver effective treatments for opioid use disorders
(OUDs). We have effective medications1 to treat OUD,
including buprenorphine, methadone, and naltrexone, but
in 2020, only about 11%2 of people with opioid use disorder
received one of them. In addition, there are significant racial
disparities3 with Black patients less likely than white patients
to receive medication treatment across multiple settings.
The barriers to treatment are high, and they include
philosophical, regulatory, administrative, and clinical

constraints. In response, clinicians and advocates have
looked to a “low threshold” approach that reduces the stigma
surrounding effective medications and facilitates their use.
Methadone and buprenorphine are both opioids, and their
use for OUD treatment is often portrayed in a stigmatizing
light as “trading one addiction for another.” But this ignores
the clear and convincing evidence that treatment with
methadone or buprenorphine substantially reduces the risk
of an opioid overdose. In a comparative effectiveness study,
Wakeman et al.4 (2020) estimated that these medications
are associated with a 76% decrease in the risk of overdose
at three months and a 59% decrease at 12 months.
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Buprenorphine stands out as the front-line treatment most
amenable to a low-threshold approach. Methadone is a
highly regulated medication that, by law, must be dispensed
by a certified treatment program with frequent, often daily,
in-person dosing when used to treat OUD; in contrast, in
contrast, buprenorphine can be prescribed by office-based
clinicians with a specialized federal waiver after an in-person
examination. They must obtain additional training in order to
obtain a federal waiver to treat more than 30 patients at a
time. Naltrexone is an opioid antagonist (meaning it blocks
the effects of opioids) and can be administered as a monthly
injection by clinicians without special training or permission.
However, naltrexone requires that patients be opioid-free
for 7-10 days, making it difficult for many patients to initiate
treatment. Because of problems in induction and retention
in treatment, questions remain5 about the real-world
effectiveness of long-acting injectable naltrexone.

in-person visits are more effective than telemedicine visits
in improving treatment outcomes or minimizing diversion.
In a recent study, Han et al.7 (2021) found that although
the use of buprenorphine increased in the U.S. between
2015 and 2019, misuse and diversion decreased slightly. In
fact, the opioids hydrocodone and oxycodone were much
more commonly misused than buprenorphine, and are not
subject to the same kind of regulatory requirements. A
National Institute on Drug Abuse report8 notes that most
of the diverted use of buprenorphine and methadone is
for the purpose of controlling withdrawal and cravings for
other opioids and not to get high. As such, diversion may
reflect the need to increase, rather than restrict, access to
prescribed buprenorphine.

During the COVID-19 pandemic, federal agencies
relaxed certain restrictions surrounding methadone and
buprenorphine. For methadone, they allowed telemedicine
appointments and additional take-home doses for
established patients; for buprenorphine, they allowed
clinicians to prescribe buprenorphine with no specialized
training for up to 30 patients and allowed prescribers to
initiate buprenorphine over the phone.

Jakubowski and Fox9 (2020) recently described four guiding
principles of low-threshold approaches to OUD treatment.
Together they help define the parameters of a medicationfirst, low-barrier approach. The principles include:

In this brief, we discuss barriers to treatment, the lowthreshold approach, the evidence of its effectiveness, and
areas for future research.

BARRIERS TO MEDICATIONS FOR OUD
TREATMENT
In a recent review, Mackey et al.6 (2020) synthesized the
evidence on barriers and facilitators of medications for
OUD. They identified four types of barriers: stigma related
to OUD medications, treatment experiences and beliefs,
logistical issues (time and costs as well as insurance and
regulatory requirements), and knowledge of OUD and the
role of medications. Stigma was the most common barrier
among patients, while logistical issues were the most
common barrier among providers and administrators.
In assessing the current research, we note that many of the
existing barriers and regulatory hurdles are themselves not
evidence-based, and have historical roots in misperceptions
and stigma around substance use. Because methadone and
buprenorphine are opioids, does the potential for diversion
and misuse warrant regulatory restrictions and in-person,
observed induction? Currently no evidence exists that

DEFINITION OF LOW-THRESHOLD APPROACH

1. Same-day treatment entry and medication
access. Given the ongoing risk of overdose, any
treatment delay, whether due to waiting lists, prior
authorizations, or clinical protocols, can be deadly.
2. Harm reduction approach. This principle
acknowledges the primacy and urgency of the goal
of reducing the harm from substance use, rather than
achieving abstinence.
3. Flexibility. Rigid protocols for in-person
appointments, psychosocial counseling, meeting
attendance, or drug testing all serve to reduce the
likelihood that a person can successfully initiate and
maintain medication therapy.
4. Wide availability in places where people with
opioid use disorder go. This includes non-traditional
settings, such as emergency departments, syringe
services programs and mobile treatment sites.

THE EVIDENCE
A low-threshold approach holds great appeal for its
potential to increase rates of medication initiation and
retention in treatment and to reach people underserved
by the standard, high-barrier care. Below we review the
evidence around each of the principles guiding a lowthreshold approach.
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1. Same-day treatment initiation can overcome
delays in initiating buprenorphine without any
negative effect on treatment retention. One
concern is that initiating medication at the first visit
might worsen retention rates, because patients
would not have already successfully completed
follow-up visits that engage them in care. But in a
recent retrospective study at an urban health center,
Jakubowski et al.10 (2020) found that 30-day retention
in treatment was high (80%) with no difference
observed for patients receiving prescriptions at their
initial encounter. Given the lack of evidence that
delaying prescribing has benefits for the patient and
the overwhelming evidence for the benefits of MOUDs
overall, the authors suggest that same-day treatment
with medication should become the standard of care.
2. Harm reduction can reduce the negative
consequences of drug use, including overdoses
and transmission of HIV, HCV, and other infectious
diseases. The salient feature of harm reduction is
the elimination of abstinence requirements to start
or continue treatment for OUD. There is no evidence
that abstinence requirements are effective in retaining
patients in medication treatment or in improving
outcomes of care. A number of studies suggest that
people with OUD who continue to use a variety of
substances, including cocaine,11 methamphetamines,
and benzodiazepines, can be successfully retained
in medication treatment12 for their OUD and achieve
similar outcomes as people who do not use these
substances.
In a qualitative study, Kapadia et al.13 (2021) described
the attributes of a nurse-led, primary care model
for buprenorphine treatment that emphasizes a
broad harm reduction approach. They identified
three important aspects of implementation: an
organizational mission to provide equitable and
low-stigma health care; providing low-threshold
buprenorphine and other clinical and social services;
and creating and retaining health care workers in
the harm reduction culture and mindset. In another
study, Kapadia et al.14 (2021) identified some of
the challenges that independent medical practices
might face in delivering low-threshold buprenorphine
treatment, including funding shortfalls and building
relationships across treatment programs, community
organizations, the legal system, and government
agencies.

3. Flexibility in the regulations and the requirements
around prescribing medication for OUDs increased
access during a global pandemic. As described
by Aronowitz et al.15 (2021), this included expanded
use of telehealth for buprenorphine prescribing, and
increasing leniency by methadone programs in their
take-home dose scheduling. Anecdotally, Wang et al.16
(2021) report that telemedicine increased access to
buprenorphine during the pandemic and is eliminating
many traditional barriers to treatment, particularly for
individuals leaving incarceration, and people who use
syringe services programs. Harris et al.17 (2022) report
an 80% retention rate in buprenorphine treatment for
patients transitioned from a street medicine program
to telemedicine in Baltimore during the pandemic.
Also in Baltimore, Nordeck et al.18 (2021) report that
a buprenorphine program consisting of pop-up clinics
and van service to vulnerable populations shifted
to telehealth during the pandemic and had 30-day
retention rates of 63%, similar to its in-person rates.
These findings are consistent with longer-term
studies of loosening the requirements around
medication prescribing. In a rural treatment setting,
Weintraub et al.19 (2021) reported that, over 3.5
years, a program prescribing medication treatment
by videoconferencing achieved retention rates
and toxicology results comparable to face-to-face
treatment. In New York City, a 7-year longitudinal
study20 of “low threshold” treatment in a public
hospital clinic (including unobserved home induction
of buprenorphine and no psychosocial counseling
requirement) found the practice to be safe and
feasible, with retention rates comparable to other
centers.
Low-barrier approaches are justified based on mixed
evidence21 about the effectiveness of requiring
counseling and other behavioral interventions, with
multiple high-quality studies showing no added
benefit of counseling compared to buprenorphine
maintenance alone. These findings have led expert
groups like the National Academy of Sciences,
Engineering and Medicine1 to recommend that “lack of
availability or utilization of behavioral interventions is
not a sufficient justification to withhold MOUDs.”
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4. Making medications widely available in nontraditional settings can increase access for
marginalized populations, such as homeless
individuals and people who inject drugs. The idea
is to meet people where they are, both in terms of
location and their receptivity to starting medication
treatment. These settings include:
a. Emergency departments (EDs). There is strong
evidence that initiating buprenorphine in EDs improves
engagement in treatment and is cost effective. In a
randomized trial, D’Onofrio et al.22 (2015) found that
ED-initiated buprenorphine treatment, compared
to a brief intervention and referral, significantly
increased treatment engagement and reduced selfreported illicit opioid use at 30 days. Further, the
intervention was cost-effective and high-value,23
with continued effectiveness at 2 months24 when
buprenorphine was continued in primary care. Despite
this strong evidence, a new national study25 indicates
that buprenorphine was prescribed after just 1 in
12 ED visits for opioid overdose. In a recent study,
Lowenstein et al.26 (2021) implemented and evaluated
a multicomponent strategy designed to increase ED
buprenorphine prescribing in an urban, academic
health system. The strategy, which included provider
training, electronic health record decision support,
integration of peer recovery specialists into clinical
teams, and the use of automated prompts, was
associated with sustained increases in ED initiation of
treatment.
b. Syringe services programs (SSPs). Now legal in 33
states, SSPs are an important setting for reaching
people who inject drugs. A number of programs
now initiate buprenorphine onsite. In one study,
Bachhuber et al.27 (2018) found that retention
rates for buprenorphine treatment in a Philadelphia
SSP were comparable to rates achieved in more
traditional settings. In Seattle, Hood et al.28 (2020)
found that an SSP was an effective point of entry
for a co-located buprenorphine treatment program,
with sustained retention and reductions in opioid
use, despite patients who had housing instability
and polysubstance use. Recently, Jakubowski
et al.29 (2021) described the implementation of
buprenorphine services in eight SSPs in New York
City, and recommended ways to facilitate treatment
through infrastructural support, training, and staffing.
Despite these successes, only 11% of SSPs30 in 2014

reported offering on-site methadone or buprenorphine
treatment.
c. M
 obile treatment sites. In June 2021, the Drug
Enforcement Administration31 allowed certified opioid
treatment programs (that dispense methadone) to add
a “mobile component” without separate registration
for those services. The new policy is designed
to encourage expansion of these programs into
communities that lack access. Weintraub et al.32 (2021)
described a mobile buprenorphine program in which
staff traveled to rural areas in a modified recreational
vehicle equipped with medical, videoconferencing,
and data collection devices. Three-month treatment
retention and opioid use outcomes were similar
to those achieved in office-based settings. Mobile
outreach and buprenorphine treatment have also been
successful in engaging hard to reach populations,
such as justice-involved individuals33 (with a mobile
van parked outside of Baltimore City jail) and those
experiencing homelessness34 (at local shelters and
homeless encampment sites).

RESEARCH QUESTIONS
While existing research on low-threshold medication
treatments, including same-day treatment, generally
shows that outcomes are not worse than traditional care,
most studies are small, short-term, and lack appropriate
controls. More rigorous comparative effectiveness and
cost effectiveness studies are needed to fully evaluate the
effects on a broad range of outcomes including retention
in treatment and overdose rates, as well as quality of life,
housing, employment, criminal justice involvement, and
family considerations. Studies should avoid a sole focus on
abstinence outcomes, which is inconsistent with the harm
reduction principle of low-threshold treatment, and may not
reflect patients’ own goals for their treatment.
As Nunes et al.35 (2021) notes, the abrupt relaxation of
regulations around medications for OUD represents a
large natural experiment, one that could yield valuable
information on the need for in-person visits, urine toxicology,
and psychosocial counseling. Do initial and recurrent inperson visits increase patient engagement, motivation,
and retention? When and for whom does psychosocial
counseling serve to improve outcomes with medication
treatment, and when does it function as a barrier? These are
empirical questions that warrant further study. Moreover,
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policy changes during the pandemic, such as allowing take-home
doses of methadone, are designed to increase access to treatment.
Understanding the actual effects of these changes on access,
outcomes and costs, both intended and unintended, will be critical
as policymakers debate making them permanent.
In addition, the impact on access to care for different populations
needs to be considered. There are longstanding equity concerns in
access to different treatments for racial and ethnic minorities; for
example, white patients are far more likely to receive buprenorphine
in office-based settings, while Black patients are more likely to
receive treatment in highly-regulated methadone clinics with long
waiting lists and burdensome demands on patients. Research is
needed to analyze the effects of low-barrier care on addressing
these known disparities.
In addition to further studies of treatment in EDs, SSPs, and mobile
settings, there are many unanswered questions about the optimal
use of telemedicine to make medication treatment of OUD more
widely available. Providers need evidence to inform clinical protocols
about how often to interact with patients, how best to monitor
use and retention in care, and when to see patients in person.
Insurers also need evidence to design and implement appropriate
reimbursement. Are there characteristics or patient factors that
can distinguish patients that would benefit from one approach or
another? How and where do people who use drugs want to receive
medication treatment, and what would encourage them to do so?

POLICY AND PRACTICE IMPLICATIONS
Out of necessity during the pandemic, policymakers lowered
barriers to medication treatment for OUD. With more than 100,000
people dying of an overdose in the past year, the urgent question
is whether to keep them lowered permanently, or even to further
relax regulations. The evidence suggests that expanding telehealth
options for buprenorphine and increasing flexibility for methadone
prescribing and dispensing have expanded access to medication
treatment, and warrant continuation. Given the effectiveness of
medications and the depth and breadth of the treatment gap,
federal and state policymakers should cast a critical eye on the rules
and regulations that reduce access, and promote a low-threshold
approach that could facilitate treatment for the vast majority of
people at high risk for overdose or death.
While regulatory changes are consistent with some of the principles
of low-threshold treatment, they are only a part of a broader
approach that seeks to directly address stigma as well as logistical
barriers. Implementing low-threshold treatment more broadly will
require providers and payers to embrace clinical paradigms that deemphasize abstinence and place a priority on initiating or re-initiating
treatment whenever and wherever individuals are ready to do so.

ABOUT LDI
Since 1967, the University of
Pennsylvania’s Leonard Davis Institute of
Health Economics (Penn LDI) has been the
leading university institute dedicated to
data-driven, policy-focused research that
improves our nation’s health and health
care. Penn LDI’s priority areas include
(1) health care access and coverage;
(2) health equity; (3) improving care for
older adults; (4) opioid epidemic; and (5)
population health. Penn LDI connects all
twelve of Penn’s schools, the University
of Pennsylvania Health System, and the
Children’s Hospital of Philadelphia through
its more than 300 Senior Fellows.
Learn more at ldi.upenn.edu.
@PennLDI

ABOUT CHERISH
The Center for Health Economics of
Treatment Interventions for Substance
Use Disorder, HCV, and HIV (CHERISH) is
a multi-institutional Center of Excellence,
funded by the National Institute on
Drug Abuse. The Center’s mission is to
develop and disseminate health economic
research on healthcare utilization, health
outcomes, and health-related behaviors
that informs substance use disorder
treatment policy and HCV and HIV care of
people who use substances. To increase
the impact of this research, CHERISH
supports research conducted at the
individual, system, and community levels.
The Center is a collaboration among
Weill Cornell Medicine, Boston Medical
Center, Boston University School of Public
Health, the University of Pennsylvania,
and the University of Miami Miller School
of Medicine.
Learn more at cherishresearch.org.
@CHERISHresearch

Leonard Davis Institute of Health Economics | Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV 5

ISSUE BRIEF

REFERENCES
1.	National Academies of Sciences, Engineering, and
Medicine. (2019). Medications for Opioid Use Disorder
Save Lives. Washington, DC: The National Academies
Press. https://doi.org/10.17226/25310
2.	Volkow, N.D. (2022). Making addiction treatment
more realistic and pragmatic: The perfect should not
be the enemy of the good. Health Affairs Forefront.
Retrieved from: https://www.healthaffairs.org/
do/10.1377/forefront.20211221.691862
3.	Hollander, M., Chang, C.H., Douaihy, A.B., Hulsey, E.,
& Donohue, J.M. (2021). Racial inequity in medication
treatment for opioid use disorder: Exploring potential
facilitators and barriers to use. Drug and Alcohol
Dependence, 227, 108927. https://doi.org/10.1016/j.
drugalcdep.2021.108927
4.	Wakeman, S.E., Larochelle, M.R., Ameli, O., Chaisson,
C.E., McPheeters, J.T., Crown, W.H., Azocar, F., &
Sanghavi, D.M. (2020). Comparative effectiveness of
different treatment pathways for opioid use disorder.
JAMA Network Open, 3(2), e1920622. https://doi.
org/10.1001/jamanetworkopen.2019.20622
5.	Jarvis, B.P., Holtyn, A.F., Subramaniam, S., Tompkins,
D.A., Oga, E.A., Bigelow, G.E., & Silverman, K. (2018).
Extended-release injectable naltrexone for opioid
use disorder: a systematic review. Addiction, 113(7),
1188–1209. https://doi.org/10.1111/add.14180
6.	Mackey, K., Veazie, S., Anderson, J., Bourne, D., &
Peterson, K. (2020). Barriers and facilitators to the
use of medications for opioid use disorder: a rapid
review. Journal of General Internal Medicine, 35(Suppl
3), 954–963. https://doi.org/10.1007/s11606-02006257-4
7.	Han, B., Jones, C.M., Einstein, E.B., & Compton, W.M.
(2021). Trends in and characteristics of buprenorphine
misuse among adults in the US. JAMA Network
Open, 4(10):e2129409. https://doi.org/10.1001/
jamanetworkopen.2021.29409
8.	National Institute on Drug Abuse (NIDA). (2021).
What is the Treatment Need Versus the Diversion Risk
for Opioid Use Disorder Treatment? Retrieved from:
https://www.drugabuse.gov/publications/researchreports/medications-to-treat-opioid-addiction/
what-treatment-need-versus-diversion-risk-opioiduse-disorder-treatment
9.	Jakubowski, A., & Fox, A. (2020). Defining lowthreshold buprenorphine treatment. Journal of
Addiction Medicine, 14(2), 95–98. https://doi.
org/10.1097/ADM.0000000000000555
10.	Jakubowski, A., Lu, T., DiRenno, F., Jadow, B.,
Giovanniello, A., Nahvi, S., Cunningham, C., & Fox,
A. (2020). Same-day vs. delayed buprenorphine
prescribing and patient retention in an office-based
buprenorphine treatment program. Journal of
Substance Abuse Treatment, 119, 108140. https://doi.
org/10.1016/j.jsat.2020.108140
11.	Weinstein, L.C., Iqbal, Q., Cunningham, A., Debates,
R., Landistratis, G., Doggett, P., & Silverio, A. (2020).
Retention of patients with multiple vulnerabilities
in a federally qualified health center buprenorphine
program: Pennsylvania, 2017–2018. American
Journal of Public Health 110, 580–586. https://doi.
org/10.2105/AJPH.2019.305525
12.	Cunningham, C.O., Giovanniello, A., Kunins,
H.V., Roose, R.J., Fox, A.D., & Sohler, N.L. (2013).
Buprenorphine treatment outcomes among opioiddependent cocaine users and non-users. American
Journal of Addiction, 22: 352-357. https://doi.
org/10.1111/j.1521-0391.2013.12032.x
13.	Kapadia, S.N., Griffin, J.L., Waldman, J., Ziebarth, N.R.,
Schackman, B.R., & Behrends, C.N. (2021). A harm
reduction approach to treating opioid use disorder in
an independent primary care practice: a qualitative
study. Journal of General Internal Medicine, 36(7),
1898–1905. https://doi.org/10.1007/s11606-02006409-6

14.	Kapadia, S.N., Griffin, J.L., Waldman, J., Ziebarth,
N.R., Schackman, B.R., & Behrends, C.N. (2021).
The experience of implementing a low-threshold
buprenorphine treatment program in a non-urban
medical practice. Substance Use & Misuse. https://
doi.org/10.1080/10826084.2021.2012484
15.	Aronowitz, S.V., Engel-Rebitzer, E., Lowenstein, M.,
Meisel, Z., Anderson, E., & South, E. (2021). “We
have to be uncomfortable and creative”: Reflections
on the impacts of the COVID-19 pandemic on
overdose prevention, harm reduction & homelessness
advocacy in Philadelphia. SSM – Qualitative Research
in Health, 1, 100013. https://doi.org/10.1016/j.
ssmqr.2021.100013
16.	Wang, L., Weiss, J., Ryan, E.B., Waldman, J., Rubin,
S., & Griffin, J.L. (2021). Telemedicine increases
access to buprenorphine initiation during the
COVID-19 pandemic. Journal of Substance Abuse
Treatment, 124, 108272. https://doi.org/10.1016/j.
jsat.2020.108272
17.	Harris, R., Rosecrans, A., Zoltick, M., Willman, C.,
Saxton, R., Cotterell, M., Bell, J., Blackwell, I., &
Page, K.R. (2022). Utilizing telemedicine during
COVID-19 pandemic for a low-threshold, streetbased buprenorphine program. Drug and Alcohol
Dependence, 109187. https://doi.org/10.1016/j.
drugalcdep.2021.109187
18.	Nordeck C.D., Buresh, M., Krawczyk, N., Fingerhood,
M., & Agus D. (2021). Adapting a low-threshold
buprenorphine program for vulnerable populations
during the COVID-19 pandemic. Journal of Addiction
Medicine, 15(5):364-369. https://doi.org/10.1097/
ADM.0000000000000774
19.	Weintraub, E., Greenblatt, A.D., Chang, J., Welsh, C.J.,
Berthiaume, A.P., Goodwin, S.R., Arnold, R., Himelhoch,
S.S., Bennett, M.E., & Belcher, A.M. (2021). Outcomes
for patients receiving telemedicine-delivered
medication-based treatment for opioid use disorder:
A retrospective chart review. Heroin Addiction and
Related Clinical Problems, 23(2), 5–12.
20.	Bhatraju, E.P., Grossman, E., Tofighi, B., McNeely, J.,
DiRocco, D., Flannery, M., Garment, A., Goldfeld, K.,
Gourevitch, M.N., & Lee, J.D. (2017). Public sector
low threshold office-based buprenorphine treatment:
outcomes at year 7. Addiction Science & Clinical
Practice, 12(1), 7. https://doi.org/10.1186/s13722-0170072-2
21.	Carroll, K.M., & Weiss, R.D. (2017). The role
of behavioral interventions in buprenorphine
maintenance treatment: A review. The American
Journal of Psychiatry, 174(8), 738–747. https://doi.
org/10.1176/appi.ajp.2016.16070792
22.	D’Onofrio, G., O’Connor, P.G., Pantalon, M.V,,
Chawarski, M.C., Busch, S.H., Owens P.H., Bernstein,
S.L., & Fiellin, D.A. (2015). Emergency department–
initiated buprenorphine/naloxone treatment for
opioid dependence: A randomized clinical trial.
JAMA, 313(16):1636–1644. https://doi.org/10.1001/
jama.2015.3474
23.	Busch, S.H., Fiellin, D.A., Chawarski, M.C., Owens, P.H.,
Pantalon, M.V., Hawk, K., Bernstein, S.L., O’Connor,
P.G., & D’Onofrio, G. (2017). Cost-effectiveness of
emergency department-initiated treatment for opioid
dependence. Addiction, 112(11), 2002–2010. https://
doi.org/10.1111/add.13900
24.	D’Onofrio, G., Chawarski, M.C., O’Connor, P.G.,
Pantalon, M.V., Busch, S.H., Owens, P.H., Hawk, K.,
Bernstein, S.L., & Fiellin, D.A. (2017). Emergency
department-initiated buprenorphine for opioid
dependence with continuation in primary care:
outcomes during and after intervention. Journal of
General Internal Medicine, 32(6), 660–666. https://
doi.org/10.1007/s11606-017-3993-2

25.	Chua, K.P., Dahlem, C.H.Y., Nguyen, T.D., Brummett,
C.M., Conti, R.M., Bohnert, A.S., Dora-Laskey, A.D.,
Kocher, K.E. (2021). Naloxone and buprenorphine
prescribing following US emergency department
visits for suspected opioid overdose: August 2019
to April 2021. Annals of Emergency Medicine,
18:S0196-0644(21)01349-4. https://doi.org/10.1016/j.
annemergmed.2021.10.005
26.	Lowenstein, M., Perrone, J., Xiong, R.A., Snider,
C.K., O’Donnell, N., Hermann, D., Rosin, R., Dees, J.,
McFadden, R., Khatri, U., Meisel, Z.F., Mitra, N., &
Delgado, M.K. (2021). Sustained implementation of
a multicomponent strategy to increase emergency
department-initiated interventions for opioid use
disorder. Annals of Emergency Medicine. https://doi.
org/10.1016/j.annemergmed.2021.10.012
27.	Bachhuber, M.A., Thompson, C., Prybylowski,
A., Benitez, J., Mazzella, S., & Barclay, D. (2018).
Description and outcomes of a buprenorphine
maintenance treatment program integrated within
Prevention Point Philadelphia, an urban syringe
exchange program. Substance Abuse, 39(2), 167–172.
https://doi.org/10.1080/08897077.2018.1443541
28.	Hood, J.E., Banta-Green, C.J., Duchin, J.S., Breuner,
J., Dell, W., Finegood, B., Glick, S.N., Hamblin, M.,
Holcomb, S., Mosse, D., Oliphant-Wells, T., & Shim,
M.M. (2020). Engaging an unstably housed population
with low-barrier buprenorphine treatment at a syringe
services program: lessons learned from Seattle,
Washington. Substance Abuse, 41(3), 356–364.
https://doi.org/10.1080/08897077.2019.1635557
29.	Jakubowski A., Rath, C., Harocopos, A., Wright, M.,
Welch, A., Kattan, J., Behrends, C.N., Lopez-Castro, T.,
& Fox, A.D. (2021). Implementation of buprenorphine
services in NYC syringe services programs: a
qualitative process evaluation. Research Square.
https://doi.org/10.21203/rs.3.rs-966790/v1
30.	Behrends, C.N., Nugent, A.V., Des Jarlais, D.C.,
Frimpong, J.A., Perlman, D.C., & Schackman, B.R.
(2018). Availability of HIV and HCV on-site testing
and treatment at syringe service programs in the
United States. Journal of Acquired Immune Deficiency
Syndromes, 79(2):e76-e78. https://doi.org/10.1097/
QAI.0000000000001792
31.	Drug Enforcement Agency (2021). DEA Finalizes
Measures to Expand Medication-Assisted Treatment.
Retrieved from: https://www.dea.gov/pressreleases/2021/06/28/dea-finalizes-measuresexpand-medication-assisted-treatment
32.	Weintraub, E., Seneviratne, C., Anane, J., Coble, K.,
Magidson, J., Kattakuzhy, S., Greenblatt, A., Welsh, C.,
Pappas, A., Ross, T.L., & Belcher, A.M. (2021). Mobile
telemedicine for buprenorphine treatment in rural
populations with opioid use disorder. JAMA Network
Open, 4(8):e2118487. https://doi.org/10.1001/
jamanetworkopen.2021.18487
33.	Krawczyk, N., Buresh, M., Gordon, M.S., Blue, T.R.,
Fingerhood, M.I., & Agus, D. (2019). Expanding
low-threshold buprenorphine to justice-involved
individuals through mobile treatment: Addressing
a critical care gap. Journal of Substance Abuse
Treatment, 103:1-8. https://doi.org/10.1016/j.
jsat.2019.05.002
34.	Carter, J., Zevin, B. & Lum, P.J. (2019). Low barrier
buprenorphine treatment for persons experiencing
homelessness and injecting heroin in San Francisco.
Addiction Science and Clinical Practice, 14, 20.
https://doi.org/10.1186/s13722-019-0149-1
35.	Nunes, E.V., Levin, F.R., Reilly, M.P., & El-Bassel, N.
(2021). Medication treatment for opioid use disorder
in the age of COVID-19: Can new regulations modify
the opioid cascade? Journal of Substance Abuse
Treatment, 122, 108196. https://doi.org/10.1016/j.
jsat.2020.108196

Leonard Davis Institute of Health Economics | Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV 6

